查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1136996

免疫查核點抑制劑市場:各藥物類別，各流通管道，各地區-規模，佔有率，展望，機會分析，2022～2030年

Immune Checkpoint Inhibitors Market, by Drug Class (Programmed Death Receptor-1 Inhibitors (Pembrolizumab, Nivolumab, Cemiplimab, & Others), Distribution Channel, & Region - Size, Share, Outlook, & Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 238 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場動態

癌症患病率的上升預計將推動全球免疫檢查點抑製劑市場。

本調查的主要特徵

  • 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球免疫查核點抑制劑市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
  • 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
  • 同時並提供市場推動因素和限制、機會、新產品發佈或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
  • 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球免疫查核點抑制劑市場的主要參與者之企業簡介。
  • 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發佈、類型升級、市場擴張和營銷策略做出明智的決策。
  • 全球免疫查核點抑制劑市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以透過全球免疫查核點抑制劑市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱的說明

第2章 市場展望

  • 報告內容
    • 市場定義和範圍
  • 摘要整理
    • 市場概述:各藥物類別
    • 市場概述:各癌症類型
    • 市場概述:各銷售管道
    • 市場概述:各地區
  • 連貫機遇地圖(COM)

第3章 市場動態，法規，及趨勢的分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 流行病學
  • 合作和夥伴關係
  • 主要的FDA核准與產品上市情景
  • 開發平台分析
  • 藥事法規情景
  • 保險償付情景
  • PEST分析
  • 波特的五力分析

第4章 免疫查核點抑制劑的全球市場-冠狀病毒(COVID-19)疫情的影響

  • 整體影響
  • 政府的配合措施
  • COVID-19市場的影響

第5章 免疫查核點抑制劑的全球市場，各藥物類別，2017年～2030年

  • 程序性死亡受體-1(PD-1)抑制劑
  • 市場規模，預測，Yo-Y成長率，2017年～2030年
  • 市場規模，預測，與前一年同期比較成長率，2017-2030年
  • 市場規模，預測，與前一年同期比較成長率，2017-2030年
  • 市場規模，預測，與前一年同期比較成長率，2017年～2030年
  • 程序性死亡受體1(PD-L1)抑制劑
  • 市場規模，預測，與前一年同期比較成長率，2017-2030年
  • PD-L1抑制劑的市場規模，預測，與前一年同期比較成長率，2017-2030年
  • 市場規模，預測，與前一年同期比較成長率，2017-2030年
  • CTL-4查核點抑制劑
  • 市場規模，預測，與前一年同期比較成長率，2017-2030年
  • 吲哚胺-2,3-雙加氧酶(IDO)抑制劑
  • 淋巴球活性化遺傳基因3抑制劑

第6章 免疫查核點抑制劑的全球市場(癌症類別):2017年～2030年

  • 肺癌症
  • 頭頸椎癌症
  • 皮膚癌症(黑色素瘤，默克爾細胞癌)
  • 血液癌症(淋巴瘤)
  • 膀胱癌(尿道表皮癌症)
  • 腎臟癌
  • 大腸癌
  • 乳癌
  • 其他

第7章 免疫查核點抑制劑的全球市場，各流通管道，2017年～2030年

  • 醫院內藥局
  • 零售藥局
  • 線上藥局

第8章 免疫查核點抑制劑的全球市場:各地區，2017年～2030年

  • 北美
  • 美國
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他的南美地區
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 中東地區
  • GCC
  • 以色列
  • 其他的中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第9章 競爭情形

  • 熱圖分析
  • 企業簡介
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.

第10章 章節

  • 參考文獻
  • 調查手法
簡介目錄
Product Code: CMI2560

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market. For instance, according to the American Cancer Society, in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.)

Key features of the study:

  • This report provides an in-depth analysis of the global immune checkpoint inhibitors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global immune checkpoint inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune checkpoint inhibitors market

Detailed Segmentation:

  • Global Immune Checkpoint Inhibitors Market, By Drug Class:
    • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
    • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
    • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
    • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Lymphocyte-Activation Gene 3 Inhibitors
  • Global Immune Checkpoint Inhibitors Market, By Cancer Type:
    • Lung Cancer
    • Head & Neck Cancer
    • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Blood Cancer (Lymphoma)
    • Bladder Cancer (Urothelial Carcinoma)
    • Renal/Kidney Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Immune Checkpoint Inhibitors Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Bristol-Myers Squibb Company*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Merck & Co., Inc.
    • Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Cancer Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Collaborations & Partnerships
  • Major FDA Approvals & Product Launch Scenario
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis
  • Porter's Five Forces Analysis

4. Global Immune Checkpoint Inhibitors Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Programmed Death Receptor-1 (PD-1) Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Pembrolizumab (Keytruda)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Nivolumab (Opdivo)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Cemiplimab (Libtayo)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Programmed Death-Ligand 1 (PD-L1) Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Atezolizumab (Tecentriq)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Avelumab (Bavencio)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Durvalumab (Imfinzi)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • CTL-4 Checkpoint Inhibitor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Ipilimumab (Yervoy)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Lymphocyte-Activation Gene 3 Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Immune Checkpoint Inhibitors Market, By Cancer Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Lung Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Head & Neck Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Blood Cancer (Lymphoma)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Bladder Cancer (Urothelial Carcinoma)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Renal/Kidney Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Colorectal Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Breast Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Immune Checkpoint Inhibitors Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact